Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 61
- Registration Number
- NCT03190265
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 6
- Registration Number
- NCT03187756
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
MUK Nine b: OPTIMUM Treatment Protocol
Phase 2
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 95
- Registration Number
- NCT03188172
- Locations
- 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, United Kingdom
TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor
Not Applicable
- Conditions
- Tumor, ColorectalTumor Gastric
- Interventions
- Biological: Tumor Specific Antigen-loaded Dendritic CellsDrug: Cyclophosphamide
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- BGI, China
- Target Recruit Count
- 20
- Registration Number
- NCT03185429
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Phase 1
Withdrawn
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cisplatinDrug: cyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-paclitaxelDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03175666
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
Phase 1
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- Biological: Neoantigen Reactive T Cells(NRTs)Biological: SHR-1210Drug: FludarabineDrug: CyclophosphamideBiological: Interleukin-2
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 40
- Registration Number
- NCT03171220
- Locations
- 🇨🇳
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, China
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
Phase 4
- Conditions
- Thalassemia Major
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT03171831
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
Phase 1
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineBiological: cetuximabDrug: CyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: oxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169777
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineBiological: CetuximabDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab-paclitaxelBiological: nivolumabDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169764
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Phase 1
Withdrawn
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: leucovorinDrug: nab-paclitaxelDrug: LovazaDrug: OxaliplatinDrug: rituximabRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-061Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169790
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath